{"entity":{"id":"paper-nct05227664-nat-med-2026","kind":"paper","name":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","aka":[],"tldr":"Published report from the trial registered as NCT05227664, in Nature Medicine (2026), chosen as the most cited paper whose own text cites the registry id.","summary":"Triple-negative breast cancer is an aggressive subtype comprising 10-20% of all breast cancer cases and has a worse prognosis than other subtypes. This open-label, multicenter, single-arm, phase 2 clinical trial evaluates the safety and efficacy of ivonescimab combined with chemotherapy as first-line treatment in female patients with locally advanced unresectable or metastatic triple-negative breast cancer who have not received previous systemic therapy. Eligible patients received ivonescimab 20 mg kg -1 intravenously every 2 weeks and paclitaxel 90 mg m - 2 or nab-paclitaxel 100 mg m - 2 intravenously on days 1, 8 and 15 of each 4-week treatment cycle. The primary endpoints were safety and the investigator-assessed objective response rate per RECIST v.1.1. A total of 36 patients were enrolled. at July 15, 2025, the median follow-up duration was 22.1 months. The primary endpoints were met. Treatment-related adverse events occurred in 36 (100.0%) patients. Grade ≥3 treatment-related adverse events were reported in 21 (58.3%) patients. No treatment-related deaths occurred. Immune-related adverse events occurred in 15 (41.7%) patients, with grade ≥3 events in 4 (11.1%) patients. Of the 35 patients evaluable for treatment efficacy, the objective response rate was 80.0% (95% confidence interval: 63.1-91.6), including 2 (5.7%) complete responses and 26 (74.3%) partial responses. Ivonescimab plus chemotherapy demonstrated encouraging antitumor activity as first-line therapy for patients with previously untreated advanced triple-negative breast cancer and merits further investigation. ClinicalTrials.gov identifier: NCT05227664.\n\nIndexed on Europe PMC as PubMed record 42587052 (DOI 10.1038/s41591-026-04564-7). Its abstract cites the registry id NCT05227664, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Nat Med 2026","url":"https://doi.org/10.1038/s41591-026-04564-7"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42587052/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/42587052"},{"label":"ClinicalTrials.gov NCT05227664","url":"https://clinicaltrials.gov/study/NCT05227664"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05227664"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-medicine"],"dependsOn":[],"notes":[],"journal":"Nature Medicine","year":2026,"doi":"10.1038/s41591-026-04564-7","pmid":"42587052","authors":"Shao X, Tian C, Chen Z, et al.","paperType":"observational","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT05227664 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-nct05227664-nat-med-2026/","neighbours":{"trial":[{"id":"nct05227664","kind":"trial","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05227664/"}],"journal":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/"}]}}